公开(公告)号：US20250057771A1

公开(公告)日：2025-02-20

申请号：US18645035

申请日：2024-04-24

Applicant: Park Therapeutics, Inc. ,  Enteris Biopharma, Inc.

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K9/28 ,  A61K9/20 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

公开(公告)号：US11998640B2

公开(公告)日：2024-06-04

申请号：US17675643

申请日：2022-02-18

Applicant: PARK THERAPEUTICS, INC. ,  ENTERIS BIOPHARMA, INC

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K9/28 ,  A61K9/20 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10

CPC classification number: A61K9/2886 ,  A61K9/2018 ,  A61K9/2081 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2893 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10 ,  A61K9/2095

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

公开(公告)号：US20190192442A1

公开(公告)日：2019-06-27

申请号：US16267902

申请日：2019-02-05

Applicant: TAURUS DEVELOPMENT COMPANY LLC ,  ENTERIS BIOPHARMA, INC

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K9/28 ,  A61K9/20 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10

CPC classification number: A61K9/2886 ,  A61K9/2018 ,  A61K9/2081 ,  A61K9/2095 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2893 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

公开(公告)号：US20230000779A1

公开(公告)日：2023-01-05

申请号：US17675643

申请日：2022-02-18

Applicant: TAURUS DEVELOPMENT COMPANY LLC ,  ENTERIS BIOPHARMA, INC

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K9/28 ,  A61K38/23 ,  A61K9/20 ,  A61P19/02 ,  A61P19/10

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

公开(公告)号：US11285113B2

公开(公告)日：2022-03-29

申请号：US16267902

申请日：2019-02-05

Applicant: TAURUS DEVELOPMENT COMPANY LLC ,  ENTERIS BIOPHARMA, INC

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K38/23 ,  A61K9/20 ,  A61K9/28 ,  A61P19/02 ,  A61P19/10

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.